Edison Oncology Venture Sweden AB (TE:ONVE) recently announced the initiation of its open-label Phase II study of 2X-121, a dual PARP-1/2 and TNKS-1/2 inhibitor, as a single agent in patients with metastatic breast cancer (mBC). The first patient, selected by OV’s 2X-121 drug response predictor (DRP) mRNA biomarker, was dosed in late June 2018. Also, OV announced that its impending merger with the Medical Prognosis Institute A/S (ST:MPIT) will happen in September 2018. OV shareholders will own 51% of the new company.
First patient dosed in 2X-121 Phase II trial
On 26 June 2018, OV announced the initiation of its Phase II 2X-121 study with the dosing of its first patient (of the 30-patient recruitment goal) with mBC selected by its 414-gene 2X-121 DRP algorithm. The primary endpoint of the open-label trial is overall tumor response according to RECIST at more than 24-weeks post-treatment. Top-line data are expected in H220. We expect the results of this trial to elucidate whether the DRP can prospectively identify responders to 2X-121.
To read the entire report Please click on the pdf File Below: